Virax Biolabs Group Limited Ordinary Shares (VRAX) is a publicly traded Healthcare sector company. As of May 21, 2026, VRAX trades at $0.30 with a market cap of $1.74M and a P/E ratio of 0.00. VRAX moved +2.30% today. Year to date, VRAX is -16.86%; over the trailing twelve months it is -70.87%. Its 52-week range spans $0.10 to $3.62. Rallies surfaces VRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Virax Biolabs Targets 180-Day ViraxImmune™ Data Readout in $25B PAIS Market: Virax Biolabs is pursuing US market entry for its ViraxImmune™ PAIS diagnostic via an LDT pathway in a $25B PAIS market and targeting an assay readout within 180 days. The debt-free company holds $6.4M cash against a $2.6M market cap despite ISO certifications and FDA Q-Sub feedback.
| Metric | Value |
|---|---|
| Price | $0.30 |
| Market Cap | $1.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.62 |
| 52-Week Low | $0.10 |
| Volume | 209.73K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
VRAX analyst coverage data. Average price target: $0.00.